← Eichor
Condition: Refractory Immune Cytopenia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Immune Cytopenia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT06787989Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06352281Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le
Phase 2 · 4 location(s) · Mayo Clinic · NCT03418038The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopeni
Phase 2 · 4 location(s) · Seoul National University Hospital · NCT05599880RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072247An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocy
Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06826430Safety Study of CC312 in Autoimmune Disease Patients
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT06888960Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character o
NA · 1 location(s) · University Hospital, Bordeaux · NCT04800458Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
NA · 1 location(s) · Anhui Provincial Hospital · NCT06973356A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Phase 1/Phase 2 · 3 location(s) · Keymed Biosciences Co.Ltd · NCT07175493Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
EARLY_Phase 1 · 2 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06519565A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06943937BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06794008
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.